449 related articles for article (PubMed ID: 20007828)
1. Suppression of experimental autoimmune uveoretinitis by inducing differentiation of regulatory T cells via activation of aryl hydrocarbon receptor.
Zhang L; Ma J; Takeuchi M; Usui Y; Hattori T; Okunuki Y; Yamakawa N; Kezuka T; Kuroda M; Goto H
Invest Ophthalmol Vis Sci; 2010 Apr; 51(4):2109-17. PubMed ID: 20007828
[TBL] [Abstract][Full Text] [Related]
2. Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis.
Haruta H; Ohguro N; Fujimoto M; Hohki S; Terabe F; Serada S; Nomura S; Nishida K; Kishimoto T; Naka T
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3264-71. PubMed ID: 21330657
[TBL] [Abstract][Full Text] [Related]
3. Suppression of experimental autoimmune uveoretinitis by regulatory dendritic cells in mice.
Usui Y; Takeuchi M; Hattori T; Okunuki Y; Nagasawa K; Kezuka T; Okumura K; Yagita H; Akiba H; Goto H
Arch Ophthalmol; 2009 Apr; 127(4):514-9. PubMed ID: 19365033
[TBL] [Abstract][Full Text] [Related]
4. Suppression of experimental autoimmune uveitis by angiotensin II type 1 receptor blocker telmisartan.
Okunuki Y; Usui Y; Nagai N; Kezuka T; Ishida S; Takeuchi M; Goto H
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2255-61. PubMed ID: 19136706
[TBL] [Abstract][Full Text] [Related]
5. Contribution of CD4+CD25+ T cells to the regression phase of experimental autoimmune uveoretinitis.
Sun M; Yang P; Du L; Zhou H; Ren X; Kijlstra A
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):383-9. PubMed ID: 19696173
[TBL] [Abstract][Full Text] [Related]
6. Oral administration of retinoic acid receptor-alpha/beta-specific ligand Am80 suppresses experimental autoimmune uveoretinitis.
Keino H; Watanabe T; Sato Y; Okada AA
Invest Ophthalmol Vis Sci; 2011 Mar; 52(3):1548-56. PubMed ID: 20861477
[TBL] [Abstract][Full Text] [Related]
7. CCR5-deficient mice develop experimental autoimmune uveoretinitis in the context of a deviant effector response.
Takeuchi A; Usui Y; Takeuchi M; Hattori T; Kezuka T; Suzuki J; Okunuki Y; Iwasaki T; Haino M; Matsushima K; Usui M
Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3753-60. PubMed ID: 16186359
[TBL] [Abstract][Full Text] [Related]
8. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses.
Hohki S; Ohguro N; Haruta H; Nakai K; Terabe F; Serada S; Fujimoto M; Nomura S; Kawahata H; Kishimoto T; Naka T
Exp Eye Res; 2010 Aug; 91(2):162-70. PubMed ID: 20420831
[TBL] [Abstract][Full Text] [Related]
9. Activation of the aryl hydrocarbon receptor suppresses sensitization in a mouse peanut allergy model.
Schulz VJ; Smit JJ; Willemsen KJ; Fiechter D; Hassing I; Bleumink R; Boon L; van den Berg M; van Duursen MB; Pieters RH
Toxicol Sci; 2011 Oct; 123(2):491-500. PubMed ID: 21804081
[TBL] [Abstract][Full Text] [Related]
10. Everolimus improves experimental autoimmune uveoretinitis.
Hennig M; Bauer D; Wasmuth S; Busch M; Walscheid K; Thanos S; Heiligenhaus A
Exp Eye Res; 2012 Dec; 105():43-52. PubMed ID: 23059401
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal stem cells ameliorate experimental autoimmune uveoretinitis by comprehensive modulation of systemic autoimmunity.
Zhang X; Ren X; Li G; Jiao C; Zhang L; Zhao S; Wang J; Han ZC; Li X
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3143-52. PubMed ID: 21296818
[TBL] [Abstract][Full Text] [Related]
12. CD4+CD25+ T regulatory cells induced by LPS-activated bone marrow dendritic cells suppress experimental autoimmune uveoretinitis in vivo.
Siepmann K; Biester S; Plsková J; Muckersie E; Duncan L; Forrester JV
Graefes Arch Clin Exp Ophthalmol; 2007 Feb; 245(2):221-9. PubMed ID: 16741709
[TBL] [Abstract][Full Text] [Related]
13. Supplementation of CD4+CD25+ regulatory T cells suppresses experimental autoimmune uveoretinitis.
Keino H; Takeuchi M; Usui Y; Hattori T; Yamakawa N; Kezuka T; Sakai JI; Usui M
Br J Ophthalmol; 2007 Jan; 91(1):105-10. PubMed ID: 16943228
[TBL] [Abstract][Full Text] [Related]
14. ITE, a novel endogenous nontoxic aryl hydrocarbon receptor ligand, efficiently suppresses EAU and T-cell-mediated immunity.
Nugent LF; Shi G; Vistica BP; Ogbeifun O; Hinshaw SJ; Gery I
Invest Ophthalmol Vis Sci; 2013 Nov; 54(12):7463-9. PubMed ID: 24150760
[TBL] [Abstract][Full Text] [Related]
15. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
Xu H; Strassmann G; Chan CC; Rizzo LV; Silver PB; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 1999 Apr; 40(5):942-50. PubMed ID: 10102291
[TBL] [Abstract][Full Text] [Related]
16. Aryl hydrocarbon receptor activation affects the dendritic cell phenotype and function during allergic sensitization.
Schulz VJ; van Roest M; Bol-Schoenmakers M; van Duursen MB; van den Berg M; Pieters RH; Smit JJ
Immunobiology; 2013 Aug; 218(8):1055-62. PubMed ID: 23433705
[TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory effect of retinoic acid on experimental autoimmune uveoretinitis.
Keino H; Watanabe T; Sato Y; Okada AA
Br J Ophthalmol; 2010 Jun; 94(6):802-7. PubMed ID: 19965837
[TBL] [Abstract][Full Text] [Related]
18. Prevention of experimental autoimmune uveoretinitis by vasoactive intestinal peptide.
Keino H; Kezuka T; Takeuchi M; Yamakawa N; Hattori T; Usui M
Arch Ophthalmol; 2004 Aug; 122(8):1179-84. PubMed ID: 15302659
[TBL] [Abstract][Full Text] [Related]
19. CTLA4-Ig suppresses development of experimental autoimmune uveitis in the induction and effector phases: Comparison with blockade of interleukin-6.
Iwahashi C; Fujimoto M; Nomura S; Serada S; Nakai K; Ohguro N; Nishida K; Naka T
Exp Eye Res; 2015 Nov; 140():53-64. PubMed ID: 26297802
[TBL] [Abstract][Full Text] [Related]
20. Amelioration of experimental autoimmune uveoretinitis by pretreatment with a pathogenic peptide in liposome and anti-CD40 ligand monoclonal antibody.
Namba K; Ogasawara K; Kitaichi N; Morohashi T; Sasamoto Y; Kotake S; Matsuda H; Iwabuchi K; Iwabuchi C; Ohno S; Onoé K
J Immunol; 2000 Sep; 165(6):2962-9. PubMed ID: 10975803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
